Diversity of the association of serum levels and genetic variants of MHC class I polypeptide-related chain A with liver fibrosis in chronic hepatitis C
暂无分享,去创建一个
M. Yeh | Chung‐Feng Huang | C. Dai | Zu-Yau Lin | Jee-Fu Huang | W. Chuang | Y. Tsai | Shu-Chi Wang | Shinn-Cherng Chen | Pei-Chien Tsai | Yu-Min Ko | Ching-Chih Lin | Kuan-Yu Chen | M. Yu | Ching-I Huang | Jee‐Fu Huang
[1] Ming‐Lung Yu,et al. Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment , 2016, EBioMedicine.
[2] Ming‐Lung Yu,et al. Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment , 2016, Clinical Cancer Research.
[3] L. N. Valenti,et al. DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection , 2015, Hepatology.
[4] M. Plummer,et al. World‐wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma , 2015, Hepatology.
[5] Aasld Idsa Hcv Guidance Panel. Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus , 2015, Hepatology.
[6] Ming‐Lung Yu,et al. Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection. , 2015, Journal of hepatology.
[7] N. Kato,et al. MICA SNPs and the NKG2D system in virus-induced HCC , 2015, Journal of Gastroenterology.
[8] T. Asselah,et al. Genomics and HCV infection: progression of fibrosis and treatment response. , 2012, Journal of hepatology.
[9] Yusuke Nakamura,et al. Soluble MICA and a MICA Variation as Possible Prognostic Biomarkers for HBV-Induced Hepatocellular Carcinoma , 2012, PloS one.
[10] Ming‐Lung Yu,et al. Chronic hepatitis C infection in the elderly , 2011, The Kaohsiung journal of medical sciences.
[11] C. Sarrazin,et al. Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[12] Yusuke Nakamura,et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma , 2011, Nature Genetics.
[13] M. Manns,et al. Hepatic expression of A disintegrin and metalloproteinase (ADAM) and ADAMs with thrombospondin motives (ADAM-TS) enzymes in patients with chronic liver diseases. , 2008, Journal of hepatology.
[14] C. Yee,et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation , 2002, Nature.
[15] M. Sakamoto,et al. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. , 1993, The Journal of general virology.
[16] P. Scheuer,et al. Classification of chronic viral hepatitis: a need for reassessment. , 1991, Journal of hepatology.
[17] N. Hiramatsu,et al. Guidelines for the Management of Hepatitis C Virus Infection , 2013, Hepatology research : the official journal of the Japan Society of Hepatology.
[18] S. Zeuzem,et al. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. , 2011, Journal of hepatology.
[19] S. Bauer,et al. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[20] C. A. Fleming,et al. The Acquisition of Data , 1969 .